Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118

Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815

Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer

Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., Haney, J., Witta, S. E., Danenberg, K. D., Domenichini, I., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji112 · Cited by 1,538

Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,220

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083

Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line

Indian Cooperative Oncology Network (ICON) (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_136_17 · Cited by 6

Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis

Liu, H., Han, G., Peng, M., Weng, Y.-M., Yuan, J., Yang, G., Yu, J., & Song, Q. (2017) · Current Medical Science · doi:10.1007/s11596-017-1819-4 · Cited by 6

EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors

Shaffer, W., Kobayashi, I. S., Sentana‐Lledo, D., Sundararaman, S. K., Lee, M. D., Rangachari, D., VanderLaan, P. A., Kobayashi, S. S., & Costa, D. B. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107250 · Cited by 5

EGFR Mutation Detection in Brazilian Patients With Non–Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing

Montella, T. C., Zalis, M. G., Zukin, M., de Lima, V. C. C., Baldotto, C. S. D. R., Marchi, P. D., Salles, P. G. D. O., Mathias, C., Barrios, C. H., Kawamura, C., et al. (2023) · JCO Global Oncology · doi:10.1200/go.22.00426 · Cited by 5

Afatinib response in a lung adenocarcinoma with novel compound S720F+L861R mutation in EGFR

Zhang, X., Jiang, W., Yang, N., & Zhang, Y. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.07.002 · Cited by 5

Molecular masquerading of rare EGFR L858M/L861R mutations as common L858R/L861Q mutations by PNA clamping assay

Hong, J. H., Jung, S., Kim, M. S., Lee, S. H., & Chung, Y. (2017) · Pathology · doi:10.1016/j.pathol.2017.01.011 · Cited by 4

How Sensitive Are Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors for Squamous Cell Carcinoma of the Lung Harboring EGFR Gene–Sensitive Mutations?

Zhou, F., Chen, X., & Zhou, C. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000046 · Cited by 4

Primary urethral adenocarcinoma harbors recurrent KRAS and EGFR alterations

Zhao, T., Iafrate, A. J., & Wu, C. (2025) · Human Pathology · doi:10.1016/j.humpath.2025.105771 · Cited by 3

Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report

Chen, J., Zhao, X., Wang, J., Liu, F., Zhang, L., Chen, Y., & Chu, Q. (2022) · Translational Cancer Research · doi:10.21037/tcr-22-510 · Cited by 3

Uncommon as an Individual, Not That Uncommon as a Whole

Deng, L., & Cheng, H. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.02.013 · Cited by 3

Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations

Chang, G., Lam, D. C.-L., Tsai, C., Chen, Y., Shih, J., Aggarwal, S., Wang, S., Kim, S., Kim, Y., Wahid, I., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01869-0 · Cited by 3

The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era

Spagnuolo, A., Muto, M., Monaco, F., Colantuoni, G., & Gridelli, C. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.12.24 · Cited by 3

Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): ‘Where the streets have no name’

Spitaleri, G., Aliaga, P. T., Mariani, G. A., Attili, I., Signore, E. D., Corvaja, C., Napoli, V. M., Cavallone, M., Etessami, J. D., Zhan, Y., et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105327 · Cited by 2

Guide to Targeted Therapies: EGFR mutations in NSCLC

Cappuzzo, F. (2014) · Springer eBooks · doi:10.1007/978-3-319-03059-3 · Cited by 3

Osimertinib in uncommon EGFR exon 21 L861R and EGFR exon 18 deletion-insertion mutant non-small cell lung cancer—case report

Wang, Y., Dorwal, P., Rajadurai, S., & Arulananda, S. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-788 · Cited by 2

Two Distinct Primary EGFR-Mutated Lung Adenocarcinoma Within the Same Patient: A Case Report

Ahmad, J. A. N., He, B., Schroeder, B., & Rosales, J. (2022) · International Journal of Cancer Care and Delivery · doi:10.53876/001c.37213 · Cited by 1

Case report: Favorable efficacy of combined afatinib and anlotinib treatment in a lung adenocarcinoma patient harboring uncommon EGFR L858M/L861R mutations

He, Y., Wu, Y., He, R., Xu, M., Chen, H., Meng, Y., Zheng, L., & Wang, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1437086 · Cited by 1

What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review

Yang, C., Wang, Y., Sun, Y., Sun, Y., Zhang, R., Wang, C., Song, Y., Zhao, W. H., & Li, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1572115 · Cited by 1

Biologie moléculaire et prise en charge des patients atteints d’adénocarcinomes du poumon

Gibault, L., Cazes, A., Narjoz, C., & Blons, H. (2014) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2013.11.005 · Cited by 2

Genomic Applications in Pulmonary Malignancies

Büttner, R., Odenthal, M., & Merkelbach‐Bruse, S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0727-4_24 · Cited by 1

A case of epidermal growth factor receptor tyrosine kinase inhibitor effectiveness in epidermal growth factor receptor mutation-positive squamous cell carcinoma

Matsumura, S., Ano, S., Kikuchi, N., Masuda, M., Osawa, H., Kondo, Y., Ishii, Y., & Hizawa, N. (2023) · SAGE Open Medical Case Reports · doi:10.1177/2050313x231159504 · Cited by 1

Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing

Mamesaya, N., Mori, K. P., Kobayashi, H., Omori, S., Ko, R., Wakuda, K., Ono, A., Kenmotsu, H., Naito, T., Murakami, H., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02826-x · Cited by 1

Clinical outcome of Brazilian patients with non-small cell lung cancer in early stage harboring rare mutations in epidermal growth factor receptor

Rúgolo, J. R. M., Baldavira, C. M., Prieto, T. G., Olivieri, E. H. R., Fabro, A. T., Rainho, C. A., Castelli, E. C., Ribolla, P. E. M., Ab’Saber, A. M., Takagaki, T. Y., et al. (2022) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2022e12409 · Cited by 1

Predictive biomarkers in diffuse gliomas and non-small cell lung cancer

Merkkiniemi, K. (2015) · Työväentutkimus Vuosikirja

Efficacy of Egfr Tyrosine Kinase Inhibitors (Egfr Tkis) in Patients with Egfr-Mutated Non-Small Cell Lung Cancer Except Both Exon 19 Deletion and Exon 21 L858R: a Retrospective Analysis in Korea

Baek, J. H., Min, Y. J., Cho, E. K., Cho, B. C., Kim, Y. B., Sun, J., Ahn, M., & Park, K. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu349.54

First-line therapy of advanced non-small cell lung cancer with activatingEGFRmutations

Zhou, C. (2012) · Informa Healthcare eBooks · doi:10.3109/9781841848679.007

Pulmonary Adenocarcinoma Transforming into Small Cell Carcinoma: An Extreme Rarity

Chhabra, S., Bhutani, N., SANGWAN, M., Agarwal, M., Chhabra, R., & Sen, R. (2016) · Journal of Cancer Science and Clinical Oncology · doi:10.15744/2394-6520.3.205

Significant Response to Gemcitabine Monotherapy in Primary Pleural Epithelioid Angiosarcoma

Tan, T. H., Cheetham, G., Scott, H. S., & Brown, M. P. (2012)

Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency

Çelik, E., Samancı, N. Ş., Karadağ, M., Demirci, N. S., Çıkman, D. İ., Derin, S., Bedir, Ş., Değerli, E., Oruç, K., Öztaş, N. Ş., et al. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220964895

EGFR-Targeted Therapies in Non-small Cell Lung Cancer

Cappuzzo, F. (2014) · Springer eBooks · doi:10.1007/978-3-319-03059-3_5

Efficacy of EGFR tyrosine kinase inhibitors in patients with non–small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)

Uehara, Y., Izumi, H., Kobayashi, I. S., Matsumoto, S., Hosomi, Y., Okuno, T., Sugisaka, J., Takase, N., Taima, K., Sasaki, S., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108479

Additional file 3 of Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Wang, Y., Zheng, R., Hu, P., Zhang, Z., Shen, S., & Li, X. (2021) · Figshare · doi:10.6084/m9.figshare.17007014

Additional file 3 of Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

Park, S., Lee, S. Y., Kim, D., Sim, Y. S., Ryu, J.-S., Choi, J., Lee, S. H., Ryu, Y. J., Lee, J. H., & Chang, J. H. (2021) · Figshare · doi:10.6084/m9.figshare.13559875

Additional file 2 of Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

Park, S., Lee, S. Y., Kim, D., Sim, Y. S., Ryu, J.-S., Choi, J., Lee, S. H., Ryu, Y. J., Lee, J. H., & Chang, J. H. (2021) · Figshare · doi:10.6084/m9.figshare.13559872

Additional file 1 of Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

Park, S., Lee, S. Y., Kim, D., Sim, Y. S., Ryu, J.-S., Choi, J., Lee, S. H., Ryu, Y. J., Lee, J. H., & Chang, J. H. (2021) · Figshare · doi:10.6084/m9.figshare.13559869

Rôle des calpaïnes extracellulaires dans la progression des adénocarcinomes lépidiques

Ruppert, A.-M. (2015) · theses.fr (ABES) · doi:10.70675/6082601cze5b6z41e9zb588zf90c85ff07c9

Conséquences de la dérégulation de MET sur le phénotype des cancers bronchiques non à petites cellules EGFR mutés devenus résistant aux inhibiteurs de tyrosine kinase d’EGFR

Baldacci, S. (2017) · doi:10.70675/ea435494z4946z4d12za5f5zd338f77b537b

Antitumoral Activity of Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harbouring Rare Epidermal Growth Factor Receptor Mutations

Oyaert, M., Demedts, I., Boone, E., Dedeurwaerdere, F., Vandorpe, J., Laere, E. D., & Breyne, J. (2015) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-015-0158-z · Cited by 9

Rare and Common EGFR Mutations in Patients with Advanced NSCLCTreated with EGFR-TKIs: A Registry-Based Study

Pešek, M., Kolek, V., Skřičková, J., Černovská, M., Koubková, L., Roubec, J., Salajka, F., Zemanová, M., Krejčí, J., Hejduk, K., et al. (2015)

Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer

Yu, L., Wang, R., Zhao, Y., Wu, Y., Wang, L., Chen, H., He, Z., Wang, Q., & Wu, Y. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231168466 · Cited by 4

Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

Wu, J.-Y., Yu, C.-J., Chang, Y.-C., Yang, C.-H., Shih, J.-Y., & Yang, P.-C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3408 · Cited by 463

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations

Klughammer, B., Brugger, W., Cappuzzo, F., Ciuleanu, T., Mok, T., Reck, M., Tan, E. H., Delmar, P., Klingelschmitt, G., Yin, A.-Y., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.107 · Cited by 98